| Filing | Date | Type | Filed with |
|---|
| Change of Director's Interest Notice x2 - KD & JD | Nov 20, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - IMU | Nov 19, 2026 | Financing | ASX |
|---|
| Final Director's Interest Notice - LR | Nov 18, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - IMU | Nov 18, 2026 | Notification letter | ASX |
|---|
| Imugene Receives $2.1M R&D Tax Refund | Nov 15, 2026 | Financing | ASX |
|---|
| Director Resignation and Committee Changes | Nov 10, 2026 | Management or board change | ASX |
|---|
| Results of 2026 Annual General Meeting | Nov 10, 2026 | Meeting outcome | ASX |
|---|
| AGM Presentation | Nov 10, 2026 | Other filings | ASX |
|---|
| Imugene selected for Poster Presentation at 2026 ASH Meeting | Nov 4, 2026 | Operations update | ASX |
|---|
| Positive amendments to Convertible Notes | Nov 2, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Further Responses in azer-cel Phase 1b Trial | Oct 18, 2026 | Operations update | ASX |
|---|
| Notification of cessation of securities - IMU | Oct 16, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Oct 14, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Oct 13, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 8, 2026 | Meeting notice | ASX |
|---|
| Dr John Le Gall appointed Chief Medical Officer | Oct 6, 2026 | Management or board change | ASX |
|---|
| azer-cel BTKi Cohort Reports new Complete & Partial Response | Oct 4, 2026 | Operations update | ASX |
|---|
| Change of Director's Interest Notice - JD | Oct 1, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - IMU | Sep 8, 2026 | Financing | ASX |
|---|
| Cleansing Notice | Sep 1, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Sep 1, 2026 | Financing | ASX |
|---|
| Change of Director's Interest Notice x4 | Sep 1, 2026 | Ownership change notice | ASX |
|---|
| Corporate Governance Statement and Appendix 4G | Aug 28, 2026 | Other filings | ASX |
|---|
| Appendix 4E and Annual Report | Aug 28, 2026 | Annual report | ASX |
|---|
| Notice under section 708A(12C)(e) of the Corporations Act | Aug 27, 2026 | Notification letter | ASX |
|---|
| Notice of Initial Substantial Holding for IMU | Aug 27, 2026 | Ownership change notice | ASX |
|---|
| Becoming a substantial holder for IMU | Aug 26, 2026 | Ownership change notice | ASX |
|---|
| Notification regarding unquoted securities - IMU | Aug 26, 2026 | Other filings | ASX |
|---|
| Notification of cessation of securities - IMU | Aug 26, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - IMU | Aug 25, 2026 | Financing | ASX |
|---|
| Amendment of Convertible Notes | Aug 20, 2026 | Financing | ASX |
|---|
| Results of Extraordinary General Meeting | Aug 18, 2026 | Meeting outcome | ASX |
|---|
| Letter To Shareholders | Aug 9, 2026 | Other filings | ASX |
|---|
| Expiry Of Listed Options | Aug 5, 2026 | Other filings | ASX |
|---|
| Final Director's Interest Notice - LC | Jul 31, 2026 | Ownership change notice | ASX |
|---|
| Notification of cessation of securities - IMU | Jul 31, 2026 | Notification letter | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 30, 2026 | Quarterly report | ASX |
|---|
| Third response in concurrent BTKi Cohort of azer-cel Trial | Jul 26, 2026 | Operations update | ASX |
|---|
| $11.1 Million Placement Completed to Advance azer-cel | Jul 6, 2026 | Financing | ASX |
|---|
| New Complete Response in the Concurrent BTKi azer-cel Cohort | Jun 30, 2026 | Other filings | ASX |
|---|
| First Complete Response in Concurrent BTKi azer-cel Cohort | Jun 29, 2026 | Other filings | ASX |
|---|
| Azer-cel Granted FDA Fast Track Designation for CLL and MZL | Jun 8, 2026 | Operations update | ASX |
|---|
| First Patient in BTKi Combination Cohort of azer-cel study | May 27, 2026 | Other filings | ASX |
|---|
| Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract | May 21, 2026 | Operations update | ASX |
|---|
| Prospectus | Mar 17, 2026 | Offer document | ASX |
|---|
| $20M placement and SPP, convertible notes amended | Mar 11, 2026 | Financing | ASX |
|---|
| 100% and 80% ORRs in Subset Indications in azer-cel study | Mar 9, 2026 | Operations update | ASX |
|---|
| Trading Halt | Mar 9, 2026 | Trading halt or suspension | ASX |
|---|
| Half Yearly Report and Accounts | Feb 25, 2026 | Interim report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 29, 2026 | Quarterly report | ASX |
|---|
| FDA Supports Strategy Toward Registration for Azer-cel | Dec 7, 2025 | Guidance | ASX |
|---|
| Strategic Collaboration with JW Therapeutics | Nov 26, 2025 | Operations update | ASX |
|---|
| S&P DJI Announces September 2025 Quarterly Rebalance | Sep 5, 2025 | Other filings | ASX |
|---|
| Final Share Purchase Plan Allotment | Aug 28, 2025 | Financing | ASX |
|---|
| Appendix 4E and Annual Report | Aug 25, 2025 | Annual report | ASX |
|---|
| Imugene Capital Raising Presentation | Jul 16, 2025 | Financing | ASX |
|---|
| Imugene Completes $22.5M Placement and c.$15M SPP | Jul 16, 2025 | Financing | ASX |
|---|
| Two Additional Complete Responses in azer-cel Ph1b trial | Jul 13, 2025 | Operations update | ASX |
|---|
| Notice of Extraordinary General Meeting/Proxy Form | May 27, 2025 | Meeting notice | ASX |
|---|
| Azer-cel Granted FDA Fast Track Designation in Blood Cancer | Mar 18, 2025 | Operations update | ASX |
|---|
| S&P DJI Announces March 2025 Quarterly Rebalance | Mar 7, 2025 | Other filings | ASX |
|---|
| Imugene Granted India Patent for Oncolytic Virotherapy CF33 | Feb 26, 2025 | Other filings | ASX |
|---|
| Imugene OnCARlytics Patent Allowance in China | Feb 25, 2025 | Other filings | ASX |
|---|
| Azer-cel demonstrates two additional Complete Responses | Feb 13, 2025 | Operations update | ASX |
|---|
| Imugene Receives A$20 million for Convertible Notes Issuance | Jan 28, 2025 | Financing | ASX |
|---|
| Imugene Receives $11.7m R&D Tax Refund | Jan 10, 2025 | Financing | ASX |
|---|
| First Australian Patient Dosed in Phase 1b azer-cel Trial | Jan 2, 2025 | Operations update | ASX |
|---|
| Issuance of Convertible Notes & Warrants for up to $46m | Dec 23, 2024 | Financing | ASX |
|---|
| Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund | Dec 18, 2024 | Other filings | ASX |
|---|
| onCARlytics Trial Doses First Patient in IT Combination Arm | Nov 10, 2024 | Other filings | ASX |
|---|
| Imugene Opens First Australian Site for azer-cel Trial | Nov 7, 2024 | Other filings | ASX |
|---|
| Complete Response in MAST Study Maintained Over Two Years | Nov 4, 2024 | Other filings | ASX |
|---|
| Imugene Receives Orphan Drug Designation for VAXINIA | Sep 18, 2024 | Operations update | ASX |
|---|
| Three Complete Responses in Azer-Cel Phase 1b Trial | Sep 1, 2024 | Operations update | ASX |
|---|
| First patient dosed in Phase 1 bile tract cancer trial | Jul 9, 2024 | Operations update | ASX |
|---|
| Imugene onCARlytics Doses First Patient in IV Combination | Jun 23, 2024 | Other filings | ASX |
|---|
| Imugene and Kincell Bio Announce Strategic Partnership | Apr 15, 2024 | Acquisition or disposal | ASX |
|---|
| Bile Tract Cancer Study Opens after MAST High Dose Clearance | Apr 14, 2024 | Operations update | ASX |
|---|
| VAXINIA and HER-Vaxx featured at the AACR Annual Meeting | Apr 7, 2024 | Operations update | ASX |
|---|
| Oncolytic Virotherapy CF33 Patent Granted in China | Apr 3, 2024 | Other filings | ASX |
|---|
| Imugene to present at 2024 Cholangiocarcinoma Conference | Apr 2, 2024 | Other filings | ASX |
|---|
| Phase 1 onCARlytics Trial Advances to Combination Arm | Mar 10, 2024 | Operations update | ASX |
|---|
| Phase 1 onCARlytics Trial Doses First Intravenous Patient | Feb 14, 2024 | Other filings | ASX |
|---|
| VAXINIA Phase 1 trial doses patients in higher dose cohorts | Jan 18, 2024 | Other filings | ASX |
|---|
| Phase 1 CF33-hNIS Study Update - Positive Early Signals | Jan 16, 2024 | Other filings | ASX |
|---|
| Imugene and NeoImmuneTech to Improve Cancer Treatments | Dec 11, 2023 | Other filings | ASX |
|---|
| New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS | Dec 5, 2023 | Other filings | ASX |
|---|
| Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine | Dec 5, 2023 | Operations update | ASX |
|---|
| FDA Fast Track Designation Granted for VAXINIA Trial Program | Nov 27, 2023 | Operations update | ASX |
|---|
| Azer-cel Hits Major Milestone in Phase 1b CAR T Trial | Nov 9, 2023 | Other filings | ASX |
|---|
| Phase 1 CF33 VAXINIA Study Update - Positive Early Signals | Nov 5, 2023 | Other filings | ASX |
|---|
| Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study | Nov 1, 2023 | Operations update | ASX |
|---|
| Imugene Phase 1 onCARlytics CD19 virus clinical trial opens | Oct 25, 2023 | Other filings | ASX |
|---|
| Imugene B Cell & OV Platforms Featured at ESMO Congress | Oct 23, 2023 | Operations update | ASX |
|---|
| Azer-cel FDA IND Transferred to Imugene | Sep 27, 2023 | Other filings | ASX |
|---|
| Imugene Closes SPP Raising $18.2 million | Sep 24, 2023 | Financing | ASX |
|---|
| Imugene PD1-Vaxx Update | Sep 11, 2023 | Other filings | ASX |
|---|
| Imugene Receives Positive Feedback From FDA | Sep 10, 2023 | Other filings | ASX |
|---|
| VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1 | Sep 3, 2023 | Other filings | ASX |
|---|
| S&P DJI Announces September 2023 Quarterly Rebalance | Sep 1, 2023 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 25, 2023 | Results | ASX |
|---|
| Imugene completes $35M Placement & Launches c.$30M SPP | Aug 17, 2023 | Financing | ASX |
|---|
| Imugene Licenses Allogeneic CD19 CAR T Cell Therapy | Aug 15, 2023 | Other filings | ASX |
|---|
| Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy | Aug 13, 2023 | Other filings | ASX |
|---|
| Imugene CF33 Oncolytic Virus Study to be Showcased at SITC | Aug 2, 2023 | Other filings | ASX |
|---|
| Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO | Jul 24, 2023 | Other filings | ASX |
|---|
| Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration | Jul 20, 2023 | Other filings | ASX |
|---|
| Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US | Jul 19, 2023 | Other filings | ASX |
|---|
| New Dose Escalation in Phase I Clinical Trial of CHECKvacc | Jul 6, 2023 | Other filings | ASX |
|---|
| HER-Vaxx induced antibodies correlated with tumour reduction | Jun 29, 2023 | Other filings | ASX |
|---|
| Imugene PD1-Vaxx patent extended to 2040 | Jun 28, 2023 | Other filings | ASX |
|---|
| Imugene Advances VAXINIA MAST Trial to Next IV Cohorts | Jun 8, 2023 | Other filings | ASX |
|---|
| Imugene doses first combination patient in PD1-Vaxx trial | May 31, 2023 | Other filings | ASX |
|---|
| FDA clears Imugene IND for onCARlytics first-in-class study | May 18, 2023 | Other filings | ASX |
|---|
| onCARlytics with ARTEMIS T cells show anti-tumour activity | May 17, 2023 | Other filings | ASX |
|---|
| onCARlytics with Artemis T cells abstract presented at ASGCT | May 2, 2023 | Other filings | ASX |
|---|
| Imugene receives $12.6m R&D tax refund | Apr 25, 2023 | Other filings | ASX |
|---|
| Imugene Images and Follows CHECKVacc in TNBC Patients | Apr 19, 2023 | Other filings | ASX |
|---|
| First patients dosed in IT & IV cohort 3 of VAXINIA trial | Apr 4, 2023 | Other filings | ASX |
|---|
| First Patients Dosed in Combination Study of VAXINIA | Mar 2, 2023 | Other filings | ASX |
|---|
| Imugene PD1-Vaxx Immunotherapy Patent Granted in the US | Feb 9, 2023 | Other filings | ASX |
|---|
| Imugene VAXINIA trial advances to Combination Cohort | Feb 1, 2023 | Other filings | ASX |
|---|
| Imugene Receives Vaxinia Ethics Approval in Australia | Jan 8, 2023 | Other filings | ASX |
|---|
| CHECKVacc Data Presented at the 2022 SABC Symposium | Dec 8, 2022 | Other filings | ASX |
|---|
| First Patient Dosed in VAXINIA Intravenous Cohort 2 | Dec 4, 2022 | Other filings | ASX |
|---|
| Imugene onCARlytics with Estrella ARTEMIS T Cells SITC | Nov 13, 2022 | Other filings | ASX |
|---|
| Dose escalates In Phase I Clinical Trial of New Oncolytic Vi | Nov 11, 2022 | Other filings | ASX |
|---|
| Imugene onCARlytics with blinatumomab SITC presentation | Nov 10, 2022 | Other filings | ASX |
|---|
| Europe Patent granted for iNKT Cell Therapy Platform | Nov 6, 2022 | Other filings | ASX |
|---|
| First patient dosed in VAXINIA intratumoral cohort 2 | Oct 30, 2022 | Other filings | ASX |
|---|
| Preclinical trial of ALA iNKT therapy and IMU onCARlytics | Sep 26, 2022 | Other filings | ASX |
|---|
| First patient IV dosed in VAXINIA Phase 1 clinical trial | Sep 20, 2022 | Other filings | ASX |
|---|
| OGTR grants VAXINIA DIR licence allowing trial expansion | Sep 19, 2022 | Other filings | ASX |
|---|
| Prospectus for the issue of institutional placement options | Sep 16, 2022 | Financing | ASX |
|---|
| IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT | Sep 12, 2022 | Financing | ASX |
|---|
| Imugene doses first patient in nextHERIZON Phase 2 trial | Sep 7, 2022 | Other filings | ASX |
|---|
| Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA | Aug 31, 2022 | Other filings | ASX |
|---|
| Annual Report and Appendix 4E | Aug 30, 2022 | Annual report | ASX |
|---|
| FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC | Aug 9, 2022 | Other filings | ASX |
|---|
| Imugene Presents New PD1-Vaxx Data at the 2022 WCLC | Aug 7, 2022 | Other filings | ASX |
|---|
| Final HER-Vaxx Phase 2 Trial Overall Survival Results | Jun 26, 2022 | Other filings | ASX |
|---|
| IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL | May 17, 2022 | Other filings | ASX |
|---|
| IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON | May 9, 2022 | Other filings | ASX |
|---|
| Clarification Announcement | May 3, 2022 | Other filings | ASX |
|---|
| Termination of Supply Agreement | May 2, 2022 | Other filings | ASX |
|---|
| Dose Escalation in Phase 1 Clinical Trial of CHECKvacc | Mar 23, 2022 | Other filings | ASX |
|---|
| Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia | Mar 22, 2022 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Clinical Trial Collaboration with Merck | Mar 14, 2022 | Other filings | ASX |
|---|
| Oncolytic Virotherapy CF33 Patent Granted in Japan | Jan 30, 2022 | Other filings | ASX |
|---|
| PD1-Vaxx Clinical Trial Supply Agreement with Roche | Jan 28, 2022 | Other filings | ASX |
|---|
| HER-Vaxx Immunotherapy Patent Granted in Europe | Jan 27, 2022 | Other filings | ASX |
|---|
| Imugene Receives $6.54 million R&D Tax Incentive | Jan 6, 2022 | Other filings | ASX |
|---|
| South Korea HERVaxx Patent Grant | Jan 5, 2022 | Other filings | ASX |
|---|
| Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx | Jan 3, 2022 | Other filings | ASX |
|---|
| FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX | Dec 12, 2021 | Other filings | ASX |
|---|
| Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc | Dec 6, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces December 2021 Quarterly Rebalance | Dec 3, 2021 | Other filings | ASX |
|---|
| Clinical Trial Supply Agreement with Merck KGaA and Pfizer | Nov 15, 2021 | Other filings | ASX |
|---|
| Investor Presentation Imugene Eureka Therapeutics | Oct 31, 2021 | Other filings | ASX |
|---|
| FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACC | Oct 20, 2021 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Immunotherapy Patent Granted in Japan | Sep 21, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces September 2021 Quarterly Rebalance | Sep 3, 2021 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials | Aug 31, 2021 | Other filings | ASX |
|---|
| Appendix 4E and Full Year Statutory Accounts | Aug 30, 2021 | Annual report | ASX |
|---|
| Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx | Aug 26, 2021 | Other filings | ASX |
|---|
| Response to ASX Query | Aug 23, 2021 | Explanation request | ASX |
|---|
| Research partnership with Celularity for solid tumors | Aug 4, 2021 | Other filings | ASX |
|---|
| Prospectus for SPP and Placement Options Offer | Jul 29, 2021 | Financing | ASX |
|---|
| Imugene completes $90 M placement and launches $5 M SPP | Jul 28, 2021 | Financing | ASX |
|---|
| Appendix 4C - Quarterly Report | Jul 23, 2021 | Quarterly report | ASX |
|---|
| FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACC | Jul 1, 2021 | Other filings | ASX |
|---|
| Investor Presentation | May 17, 2021 | Other filings | ASX |
|---|
| Prestigious Research Journal Publish HER-Vaxx Phase 1B Data | Apr 29, 2021 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 23, 2021 | Quarterly report | ASX |
|---|
| Imugene announces clinical milestone for HER-Vaxx | Apr 20, 2021 | Other filings | ASX |
|---|
| Imugene Oncolytic Virus Presentation at AACR 2021 Meeting | Apr 11, 2021 | Other filings | ASX |
|---|
| Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX | Apr 6, 2021 | Other filings | ASX |
|---|
| S&P DJI Announces March 2021 Quarterly Rebalance | Mar 12, 2021 | Other filings | ASX |
|---|
| Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting | Mar 10, 2021 | Other filings | ASX |
|---|
| Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial | Feb 11, 2021 | Other filings | ASX |
|---|
| Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial | Jan 20, 2021 | Other filings | ASX |
|---|
| IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIM | Jan 6, 2021 | Other filings | ASX |
|---|
| Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial | Dec 16, 2020 | Other filings | ASX |
|---|
| Imugene Receives $4.82 million R&D Tax Incentive | Dec 10, 2020 | Other filings | ASX |
|---|
| Imugene First Patient Dosed in PD1-VAXX Clinical Trial | Nov 30, 2020 | Other filings | ASX |
|---|
| Imugene HER Vaxx shows positive Overall Survival in trial | Nov 22, 2020 | Other filings | ASX |
|---|
| Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA | Nov 1, 2020 | Other filings | ASX |
|---|
| Imugene Immunotherapy Combination Patent Granted in US | Oct 1, 2020 | Other filings | ASX |
|---|
| Imugene Secures $5.7 million Option Underwriting Agreement | Sep 8, 2020 | Other filings | ASX |
|---|
| Imugene Receives PD1-VAXX Ethics Trial Approval in USA | Sep 3, 2020 | Other filings | ASX |
|---|
| Appendix 4E & Annual Report to shareholders | Aug 31, 2020 | Annual report | ASX |
|---|
| Imugene Receives Third PD1-VAXX Ethics Trial Approval | Aug 20, 2020 | Other filings | ASX |
|---|
| Imugene Receives Clinical Guidance from US FDA for Vaxinia | Aug 5, 2020 | Guidance | ASX |
|---|
| Imugene Receives Second PD1-VAXX Ethics Trial Approval | Jul 16, 2020 | Other filings | ASX |
|---|
| Imugene Receives Ethics Approval to Start PD1-VAXX Trial | Jul 13, 2020 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Phase 2 Clinical Update | May 3, 2020 | Other filings | ASX |
|---|
| Imugene PD1-Vaxx Immunotherapy Update | Jan 27, 2020 | Other filings | ASX |
|---|
| Imugene HER-Vaxx Immunotherapy Patent Granted in US | Jan 13, 2020 | Other filings | ASX |
|---|
This page holds 200 of 258 filings.